OptimizeRx Corp. announced a data collaboration with Experian Inc. at the Consumer Electronics Show in Las Vegas. The partnership will map OptimizeRx’s patented Micro‑Neighborhood® audiences to Experian’s identity graph, creating a privacy‑safe channel that lets life‑science brands activate and measure audiences across multiple media channels.
The integration extends OptimizeRx’s reach beyond its existing point‑of‑care and direct‑to‑consumer platforms. By combining real‑world clinical data with Experian’s extensive consumer identifiers, the alliance will enable life‑science marketers to target audiences at ZIP+9 granularity while preserving privacy compliance and reducing audience loss during media onboarding.
The deal is part of OptimizeRx’s broader strategy to convert high‑margin data services into subscription contracts and broaden its audience‑activation capabilities. Management said the partnership will accelerate the company’s subscription‑conversion trajectory and open new revenue streams that strengthen its competitive moat.
In its most recent earnings report, OptimizeRx posted revenue of $26.1 million and earnings per share of $0.20, beating analyst estimates of $23.83 million and $0.03, respectively. The company’s CEO, Stephen L. Silvestro, highlighted the strong, profitable growth that is “setting the stage for sustained strength ahead.” The Experian collaboration is expected to build on that momentum by delivering measurable ROI to pharmaceutical clients.
Drew Teller, Director of Strategic Media Partnerships, said the collaboration “combines Experian’s best‑in‑class consumer data and robust identity infrastructure with OptimizeRx’s privacy‑safe targeting methodology, giving life‑science and agency clients a uniquely integrated solution that improves audience quality and measurability across all channels.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.